The takeaway
Trevi Therapeutics Inc shows a pronounced seasonal pattern over 7 years of data — strongest in June (+14.9%) and softest in August (−6.1%).
Right now
In July, the stock has fallen 57% of years, averaging −1.7%, roughly 3.9 pts behind the S&P 500.
The full picture
Trevi Therapeutics Inc's most dependable month has been June, higher in 5 of 7 years; August has been its least reliable, up just 14% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in March (+24.2 pts); it has trailed the market most in August (−6.4 pts).
“vs S&P” is Trevi Therapeutics Inc’s average for a month minus the S&P 500’s average for that same month — isolating Trevi Therapeutics Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, June has closed higher 80% of the time versus 71% across the last 7 years — the pattern is holding.
Figures are the typical (median) June return and how often it rose — the last 5 years versus the last 7(the heatmap’s default window). This verdict stays anchored to that 7-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Strip the year back and a single month does the heavy lifting: June, up in 5 of 7 Junes while the other eleven tend to blur together.
A typical June brings +10.6%, a shade under the +14.9% average. That reliability comes with real swings, mind — even June ranges by 35.3% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: June has cleared the S&P 500 by +14.7 points above the index. That consistency sets it apart from the field, where the average stock manages June only about 52% of the time.
A few other months pull their weight: January and February have also closed higher more often than not. The weaker half of the year is plainer: August has been the soft spot — the weakest of 6 months that average a loss (−6.1%), and the edge isn't year-round — the stock has trailed the S&P 500 in August, October, and November. Its roughest month on record was a −51.0% September in 2022 — a reminder of how hard even a seasonal name can fall.
A long streak recently broke — June had risen 5 years straight before a −13.4% reading in 2025. Reassuringly, the tendency has held its shape: the recent five years still track the years behind them.
The takeaway is less about when to buy than what to expect: June aside, the stock's months offer little reliable tilt. With a short 7-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (June), its worst (August), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2019 its best month (June, +14.9%) has run well ahead of its worst (August, −6.1%) — the heatmap above shows how steady that gap has been year to year.
June has been the strongest, averaging +14.9% and closing higher in 5 of 7 years since 2019.
It's the weakest, averaging −6.1% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade